These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 28333879)

  • 1. INTRAVITREAL AFLIBERCEPT INJECTION FOR CHOROIDAL NEOVASCULARIZATION DUE TO PRESUMED OCULAR HISTOPLASMOSIS SYNDROME: The HANDLE Study.
    Toussaint BW; Kitchens JW; Marcus DM; Miller DM; Kingdon ML; Holcomb D; Ivey K
    Retina; 2018 Apr; 38(4):755-763. PubMed ID: 28333879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
    Ehrlich R; Ciulla TA; Maturi R; Kheradiya NS; Hrisomalos N; Shulman S; Guess MG; Coyle E; Harris A
    Retina; 2009; 29(10):1418-23. PubMed ID: 19898179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection.
    Walia HS; Shah GK; Blinder KJ
    Can J Ophthalmol; 2016 Apr; 51(2):91-6. PubMed ID: 27085265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
    Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
    Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
    Heier JS; Clark WL; Boyer DS; Brown DM; Vitti R; Berliner AJ; Kazmi H; Ma Y; Stemper B; Zeitz O; Sandbrink R; Haller JA
    Ophthalmology; 2014 Jul; 121(7):1414-1420.e1. PubMed ID: 24679444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INTRAVITREAL INJECTION OF AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY: A 3-YEAR FOLLOW-UP.
    Maruyama-Inoue M; Sato S; Yamane S; Kadonosono K
    Retina; 2018 Oct; 38(10):2001-2009. PubMed ID: 28816730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
    BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization in ocular histoplasmosis.
    Hu J; Hoang QV; Chau FY; Blair MP; Lim JI
    Retin Cases Brief Rep; 2014; 8(1):24-9. PubMed ID: 25372202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization.
    Wang JK; Huang TL; Chang PY; Chen YT; Chang CW; Chen FT; Hsu YR; Chen YJ
    Sci Rep; 2018 Sep; 8(1):14389. PubMed ID: 30258077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy in a Predominantly Non-Asian Population: RIVAL Results.
    Farooq A; Frazier H; Marcus WB; Fechter C; Singh H; Marcus DM
    Ophthalmic Surg Lasers Imaging Retina; 2017 Jan; 48(1):34-52. PubMed ID: 28060392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing.
    Inoue M; Yamane S; Taoka R; Arakawa A; Kadonosono K
    Retina; 2016 Aug; 36(8):1527-34. PubMed ID: 26710307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRN Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Ocular Histoplasmosis.
    Wood EH; Whitted RJ; Stone TW; Isernhagen RD; Wood WJ; Holcomb DM; Kitchens JW
    Ophthalmic Surg Lasers Imaging Retina; 2018 Jan; 49(1):20-26. PubMed ID: 29304262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial.
    Lee WK; Iida T; Ogura Y; Chen SJ; Wong TY; Mitchell P; Cheung GCM; Zhang Z; Leal S; Ishibashi T;
    JAMA Ophthalmol; 2018 Jul; 136(7):786-793. PubMed ID: 29801063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials.
    Khurana RN; Rahimy E; Joseph WA; Saroj N; Gibson A; Vitti R; Berliner AJ; Chu K; Cheng Y; Boyer DS
    Am J Ophthalmol; 2019 Apr; 200():161-168. PubMed ID: 30664844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
    Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
    Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.
    Wakabayashi T; Ikuno Y; Gomi F
    Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.
    Ikuno Y; Ohno-Matsui K; Wong TY; Korobelnik JF; Vitti R; Li T; Stemper B; Asmus F; Zeitz O; Ishibashi T;
    Ophthalmology; 2015 Jun; 122(6):1220-7. PubMed ID: 25745875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration.
    Takayama K; Kaneko H; Sugita T; Maruko R; Hattori K; Ra E; Kawano K; Kataoka K; Ito Y; Terasaki H
    Ophthalmologica; 2017; 237(2):105-110. PubMed ID: 28231566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION.
    Cho HJ; Hwang HJ; Kim HS; Han JI; Lee DW; Kim JW
    Retina; 2018 Nov; 38(11):2150-2158. PubMed ID: 28984737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.